Kymera Therapeutics, Inc.
KYMR
$82.21
-$2.29-2.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1,097.39% | 3.84% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1,097.39% | 3.84% | |||
| Cost of Revenue | 17.10% | 13.14% | |||
| Gross Profit | 21.20% | -13.50% | |||
| SG&A Expenses | 20.21% | -2.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.62% | 10.21% | |||
| Operating Income | 14.04% | -10.41% | |||
| Income Before Tax | 20.40% | -5.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 20.40% | -5.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.40% | -5.85% | |||
| EBIT | 14.04% | -10.41% | |||
| EBITDA | 15.73% | -13.57% | |||
| EPS Basic | 26.63% | -2.77% | |||
| Normalized Basic EPS | 26.61% | -7.83% | |||
| EPS Diluted | 26.63% | -2.77% | |||
| Normalized Diluted EPS | 26.61% | -7.83% | |||
| Average Basic Shares Outstanding | 8.47% | 2.99% | |||
| Average Diluted Shares Outstanding | 8.47% | 2.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||